-
公开(公告)号：US20120052073A1
公开(公告)日：2012-03-01
申请号：US13169400
申请日：2011-06-27
申请人： Larry L. Green , Qing Zhou , Bruce A. Keyt , Xiao-Dong Yang , Stephen Charles Emery , David Charles Blakey
发明人： Larry L. Green , Qing Zhou , Bruce A. Keyt , Xiao-Dong Yang , Stephen Charles Emery , David Charles Blakey
IPC分类号： A61K39/395 , C12N15/13 , A61P35/00 , C12N5/20 , C07K16/28 , C12N5/10 , C07K16/22 , C12N15/63
CPC分类号： C07K16/22 , A61K39/39558 , A61K2039/505 , C07K14/515 , C07K2317/21 , C07K2317/56 , C07K2317/76 , C07K2317/92
摘要： Antibodies directed to the antigen Ang-2 and uses of such antibodies are described. In particular, fully human monoclonal antibodies directed to the antigen Ang-2. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies.
摘要翻译： 描述针对抗原Ang-2的抗体和这种抗体的用途。 特别是针对抗原Ang-2的完全人单克隆抗体。 编码的核苷酸序列和包含重链和轻链免疫球蛋白分子的氨基酸序列，特别是对应于跨越框架区和/或互补决定区（CDR）的连续重链和轻链序列的序列，特别是从FR1至FR4或CDR1至CDR3 。 表达这种免疫球蛋白分子和单克隆抗体的杂交瘤或其它细胞系。
-
公开(公告)号：US07973140B2
公开(公告)日：2011-07-05
申请号：US11311939
申请日：2005-12-19
申请人： Larry L. Green , Qing Zhou , Bruce A. Keyt , Xiao-Dong Yang , Stephen Charles Emery , David Charles Blakey
发明人： Larry L. Green , Qing Zhou , Bruce A. Keyt , Xiao-Dong Yang , Stephen Charles Emery , David Charles Blakey
IPC分类号： C07K16/22
CPC分类号： C07K16/22 , A61K39/39558 , A61K2039/505 , C07K14/515 , C07K2317/21 , C07K2317/56 , C07K2317/76 , C07K2317/92
摘要： Antibodies directed to the antigen Ang-2 and uses of such antibodies are described. In particular, fully human monoclonal antibodies directed to the antigen Ang-2. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies.
摘要翻译： 描述针对抗原Ang-2的抗体和这种抗体的用途。 特别是针对抗原Ang-2的完全人单克隆抗体。 编码的核苷酸序列和包含重链和轻链免疫球蛋白分子的氨基酸序列，特别是对应于跨越框架区和/或互补决定区（CDR）的连续重链和轻链序列的序列，特别是从FR1至FR4或CDR1至CDR3 。 表达这种免疫球蛋白分子和单克隆抗体的杂交瘤或其它细胞系。
-
公开(公告)号：US20080267971A1
公开(公告)日：2008-10-30
申请号：US11793720
申请日：2005-12-19
申请人： Larry L. Green , Qing Zhou , Bruce A. Keyt , Xia-dong Yang , Stephen Charles Emery , David C. Blakey
发明人： Larry L. Green , Qing Zhou , Bruce A. Keyt , Xia-dong Yang , Stephen Charles Emery , David C. Blakey
CPC分类号： C07K16/22 , A61K39/39558 , A61K2039/505 , C07K14/515 , C07K2317/21 , C07K2317/56 , C07K2317/76 , C07K2317/92
摘要： Antibodies directed to the antigen Ang-2 and uses of such antibodies are described. In particular, fully human monoclonal antibodies directed to the antigen Ang-2. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementary determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3. Hybridomas or other cell lines expressing such immunoglobin molecules and monoclonal antibodies.
摘要翻译： 描述针对抗原Ang-2的抗体和这种抗体的用途。 特别是针对抗原Ang-2的完全人单克隆抗体。 编码重组和轻链免疫球蛋白分子的核苷酸序列和氨基酸序列，特别是对应于跨越框架区和/或互补决定区（CDR）的连续重链和轻链序列的序列，特别是从FR1至FR4或CDR1至CDR3 。 杂交瘤或表达这种免疫球蛋白分子的其它细胞系和单克隆抗体。
-
4.发明授权Gene construct encoding a heterologous prodrug-activating enzyme and a cell targeting moiety 失效编码异源前药活化酶和细胞靶向部分的基因构建体公开(公告)号：US06339070B1
公开(公告)日：2002-01-15
申请号：US09423439
申请日：1999-11-09
IPC分类号： A61F4800
CPC分类号： B82Y5/00 , A61K38/00 , A61K47/6899 , A61K48/00 , C07K16/3007 , C07K2319/00 , C12N9/48 , C12N2799/022 , Y10S977/804
摘要： The invention provides a gene construct encoding a cell targeting moiety and a heterologous prodrug activating enzyme for use as a medicament in a mammalian host wherein the gene construct is capable of expressing the cell targeting moiety and enzyme as a conjugate within a target cell in the mammalian host and wherein the conjugate is directed to leave the cell thereafter for selective localisation at a cell surface antigen recognised by the cell targeting moiety.
摘要翻译： 本发明提供编码细胞靶向部分和异源前药活化酶的基因构建体，其用作哺乳动物宿主中的药物，其中所述基因构建体能够在哺乳动物的靶细胞内表达细胞靶向部分和酶作为缀合物 宿主，其中缀合物被引导离开细胞，然后在由细胞靶向部分识别的细胞表面抗原上进行选择性定位。
-
5.发明申请COMBINATION OF ANGIOPOIETIN-2 ANTAGONIST AND OF VEGF-A, KDR AND/OR FLTL ANTAGONIST FOR TREATING CANCER 审中-公开血管紧张素-2拮抗剂与VEGF-A，KDR和/或FLTL拮抗剂联合用于治疗癌症公开(公告)号：US20090123474A1
公开(公告)日：2009-05-14
申请号：US12097384
申请日：2006-12-12
IPC分类号： A61K39/395
CPC分类号： C07K16/18 , A61K31/404 , A61K31/44 , A61K31/517 , A61K39/3955 , A61K45/06 , A61K2039/505 , A61K2039/507 , A61M2205/52 , C07K16/22 , C07K16/2863 , C07K16/30 , C07K2317/21 , C07K2317/24 , C07K2317/33 , C07K2317/76 , C07K2317/92 , A61K2300/00
摘要： The invention relates to agents which possess anti-angiogenic activity and are accordingly useful in methods of treatment of disease states associated with angiogenesis in the animal or human body. More specifically the invention concerns a combination of an antagonist of the biological activity of Angiopoietin-2 and an antagonist of the biological activity of VEGF-A, and/or KDR, and/or Flt1, and uses of such antagonists.
摘要翻译： 本发明涉及具有抗血管生成活性的试剂，因此可用于治疗与动物或人体血管生成相关的疾病状态的方法。 更具体地，本发明涉及促血管生成素-2的生物活性的拮抗剂和VEGF-A，和/或KDR和/或Flt1的生物活性的拮抗剂和这些拮抗剂的用途的组合。
-
公开(公告)号：US20080152587A1
公开(公告)日：2008-06-26
申请号：US11733157
申请日：2007-04-09
申请人： Qing Zhou , Stephen Charles Emery , Paul Elvin
发明人： Qing Zhou , Stephen Charles Emery , Paul Elvin
CPC分类号： C07K16/2896 , A61K2039/505 , C07K2317/21 , C07K2317/73 , C07K2317/76 , C07K2317/92
摘要： Targeted binding agents directed to the antigen uPAR and uses of such antibodies are described. In particular, fully human monoclonal antibodies directed to the antigen uPAR. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies.
摘要翻译： 描述了针对抗原uPAR的靶向结合剂和这些抗体的用途。 特别是针对抗原uPAR的完全人单克隆抗体。 编码的核苷酸序列和包含重链和轻链免疫球蛋白分子的氨基酸序列，特别是对应于跨越框架区和/或互补决定区（CDR）的连续重链和轻链序列的序列，特别是从FR1至FR4或CDR1至CDR3 。 表达这种免疫球蛋白分子和单克隆抗体的杂交瘤或其它细胞系。
-
公开(公告)号：US20120108797A1
公开(公告)日：2012-05-03
申请号：US13193167
申请日：2011-07-28
申请人： Paul Elvin , Stephen Charles Emery , Qing Zhou
发明人： Paul Elvin , Stephen Charles Emery , Qing Zhou
IPC分类号： C07K16/28
CPC分类号： C07K16/2896 , A61K2039/505 , C07K2317/21 , C07K2317/73 , C07K2317/76 , C07K2317/92
摘要： Targeted binding agents directed to the antigen uPAR and uses of such antibodies are described. In particular, fully human monoclonal antibodies directed to the antigen uPAR. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementary determine regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies.
摘要翻译： 描述了针对抗原uPAR的靶向结合剂和这些抗体的用途。 特别是针对抗原uPAR的完全人单克隆抗体。 编码的核苷酸序列和包含重链和轻链免疫球蛋白分子的氨基酸序列，特别是对应于跨越框架区和/或互补决定区（CDR）的连续重链和轻链序列的序列，特别是从FR1至FR4或CDR1至CDR3 。 表达这种免疫球蛋白分子和单克隆抗体的杂交瘤或其它细胞系。
-
公开(公告)号：US08026344B2
公开(公告)日：2011-09-27
申请号：US11733157
申请日：2007-04-09
申请人： Qing Zhou , Stephen Charles Emery , Paul Elvin
发明人： Qing Zhou , Stephen Charles Emery , Paul Elvin
IPC分类号： C07K16/00 , C07K16/46 , C07K16/24 , A61K39/395
CPC分类号： C07K16/2896 , A61K2039/505 , C07K2317/21 , C07K2317/73 , C07K2317/76 , C07K2317/92
摘要： Targeted binding agents directed to the antigen uPAR and uses of such antibodies are described. In particular, fully human monoclonal antibodies directed to the antigen uPAR. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies.
摘要翻译： 描述了针对抗原uPAR的靶向结合剂和这些抗体的用途。 特别是针对抗原uPAR的完全人单克隆抗体。 编码的核苷酸序列和包含重链和轻链免疫球蛋白分子的氨基酸序列，特别是对应于跨越框架区和/或互补决定区（CDR）的连续重链和轻链序列的序列，特别是从FR1至FR4或CDR1至CDR3 。 表达这种免疫球蛋白分子和单克隆抗体的杂交瘤或其它细胞系。
-
公开(公告)号：US20090123476A1
公开(公告)日：2009-05-14
申请号：US12296593
申请日：2007-04-09
申请人： Paul Elvin , Stephen Charles Emery , Qing Zhou
发明人： Paul Elvin , Stephen Charles Emery , Qing Zhou
CPC分类号： C07K16/2896 , A61K2039/505 , C07K2317/21 , C07K2317/73 , C07K2317/76 , C07K2317/92
摘要： Targeted binding agents directed to the antigen uPAR and uses of such antibodies are described. In particular, fully human monoclonal antibodies directed to the antigen uPAR. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies.
摘要翻译： 描述了针对抗原uPAR的靶向结合剂和这些抗体的用途。 特别是针对抗原uPAR的完全人单克隆抗体。 编码的核苷酸序列和包含重链和轻链免疫球蛋白分子的氨基酸序列，特别是对应于跨越框架区和/或互补决定区（CDR）的连续重链和轻链序列的序列，特别是从FR1至FR4或CDR1至CDR3 。 表达这种免疫球蛋白分子和单克隆抗体的杂交瘤或其它细胞系。
-
10.发明授权Anti-CEA antibody designated 806.077, hybridoma and method of manufacture 失效抗CEA抗体命名为806.077，杂交瘤及其制造方法公开(公告)号：US06277599B1
公开(公告)日：2001-08-21
申请号：US09171945
申请日：1998-10-29
IPC分类号： C12N1513
CPC分类号： B82Y5/00 , A61K38/00 , A61K47/6899 , C07K14/70532 , C07K16/3007 , C07K2317/24 , C07K2319/00 , C12N9/52 , C12N9/6421
摘要： An anti-CEA monoclonal antibody, designated 806.077, of murine origin is useful for the diagnosis and therapy of cancer. The antibody complementarity determining regions have the following sequences: heavy chain CDR1 DNYMH, CDR2 WIDPENGDTE YAPKFRG, CDR3 LIYAGYLAMD Y; and light chain CDR1 SASSSVTYMH, CDR2 STSNLAS, CDR3 QQRSTYPLT. The antibody optionally is humanized and can be in the form of a conjugate with either an enzyme, such as carboxypeptidase, or a co-stimulatory molecule such as the extracellular domain of human B7.1.
摘要翻译： 抗原CEA单克隆抗体，命名为806.077，来自鼠源可用于诊断和治疗癌症。 抗体互补决定区具有以下序列：重链CDR1 DNYMH，CDR2 WIDPENGDTE YAPKFRG，CDR3 LIYAGYLAMD Y; 和轻链CDR1 SASSSVTYMH，CDR2 STSNLAS，CDR3 QQRSTYPLT。 抗体任选地是人源化的，并且可以是与酶如羧肽酶或共刺激分子如人B7.1的细胞外结构域的缀合物的形式。
-
-
-
-
-
-
-
-
-
搜索结果
11 条记录 (耗时 0.052 秒)